DK0539518T3 - Fremgangsmåde til identifikation af forbindelser, der fungerer som agonister eller antagonister for proteiner, der er involveret i signaltransduktion - Google Patents

Fremgangsmåde til identifikation af forbindelser, der fungerer som agonister eller antagonister for proteiner, der er involveret i signaltransduktion

Info

Publication number
DK0539518T3
DK0539518T3 DK91915183T DK91915183T DK0539518T3 DK 0539518 T3 DK0539518 T3 DK 0539518T3 DK 91915183 T DK91915183 T DK 91915183T DK 91915183 T DK91915183 T DK 91915183T DK 0539518 T3 DK0539518 T3 DK 0539518T3
Authority
DK
Denmark
Prior art keywords
pigment
test cells
exogenous
disposition
gpc
Prior art date
Application number
DK91915183T
Other languages
Danish (da)
English (en)
Inventor
Michael R Lerner
Ethan A Lerner
Original Assignee
Brl Screening Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27070955&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0539518(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brl Screening Inc filed Critical Brl Screening Inc
Application granted granted Critical
Publication of DK0539518T3 publication Critical patent/DK0539518T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
DK91915183T 1990-07-19 1991-07-17 Fremgangsmåde til identifikation af forbindelser, der fungerer som agonister eller antagonister for proteiner, der er involveret i signaltransduktion DK0539518T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55572490A 1990-07-19 1990-07-19
US07/732,476 US5462856A (en) 1990-07-19 1991-07-16 Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins
PCT/US1991/005046 WO1992001810A1 (en) 1990-07-19 1991-07-17 Methods of identifying compounds that act as agonists or antagonists for proteins involved in signal transduction

Publications (1)

Publication Number Publication Date
DK0539518T3 true DK0539518T3 (da) 2001-11-12

Family

ID=27070955

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91915183T DK0539518T3 (da) 1990-07-19 1991-07-17 Fremgangsmåde til identifikation af forbindelser, der fungerer som agonister eller antagonister for proteiner, der er involveret i signaltransduktion

Country Status (9)

Country Link
US (2) US5462856A (ja)
EP (1) EP0539518B1 (ja)
JP (1) JP3270041B2 (ja)
AT (1) ATE199980T1 (ja)
CA (1) CA2087614C (ja)
DE (1) DE69132564T2 (ja)
DK (1) DK0539518T3 (ja)
ES (1) ES2157890T3 (ja)
WO (1) WO1992001810A1 (ja)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138621A1 (de) * 1991-11-25 1993-06-17 Boehringer Ingelheim Int Verfahren zum screenen von substanzen mit modulierender wirkung auf einen rezeptorabhaengigen zellulaeren signaluebertragungsweg
WO1994002515A1 (en) * 1992-07-21 1994-02-03 Bunsen Rush Laboratories Inc. Oligomer library formats and methods relating thereto
IL110298A (en) * 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
IT1261847B (it) * 1993-09-01 1996-06-03 San Romanello Centro Fond Metodo per marcare cellule eucariote.
FR2713645A1 (fr) * 1993-12-08 1995-06-16 Inst Nat Sante Rech Med Polypeptides à activité de récepteur aux mélanocortines, médicaments les comprenant, séquences codant pour eux, sondes, vecteurs et hôtes les exprimant et application au criblage de médicaments.
JPH10502245A (ja) * 1994-06-29 1998-03-03 メルク エンド カンパニー インコーポレーテッド 改変ｇ−蛋白質結合リセプタ
CA2195768A1 (en) * 1994-08-11 1996-02-22 Shuji Hinuma G protein coupled receptor protein, production, and use thereof
JPH10504457A (ja) * 1994-08-16 1998-05-06 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド カルシトニンレセプター
US6806061B1 (en) 1995-01-19 2004-10-19 Children's Medical Center Corporation G protein-coupled receptor gene and methods of use therefor
US6537764B1 (en) 1995-01-19 2003-03-25 Children's Medical Center Corporation Method of identifying inhibitors of C—C chemokine receptor 3
US6090575A (en) * 1995-03-30 2000-07-18 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein coupled receptor GPR1
US5998164A (en) * 1995-03-30 1999-12-07 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein coupled receptor GPRZ
CA2221616A1 (en) * 1995-06-06 1996-12-12 Mark D. Adams Human g-protein receptor hibef51
EP1148126A3 (en) * 1995-06-06 2003-12-03 Human Genome Sciences, Inc. Human G-protein chemokine receptor HDGNR10 (CCR5 receptor)
CA2221706A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. G-protein receptor htnad29
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
AU716407B2 (en) * 1995-08-14 2000-02-24 Cornell Research Foundation Inc. Regulation of cellular functions by ectopic expression of non-endogenous cell signalling receptors
AU7622396A (en) * 1995-11-22 1997-06-11 Ciba-Geigy Ag Therapeutic agents and screening method
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
AU730137B2 (en) * 1996-01-24 2001-03-01 H. Lundbeck A/S DNA encoding galanin GALR2 receptors and uses thereof
US5972624A (en) * 1996-01-24 1999-10-26 Synaptic Pharmaceutical Corporation Method of identifying ligands which bind recombinant galanin receptor (GALR2)
EP0789076A3 (en) * 1996-02-07 1999-04-14 Takeda Chemical Industries, Ltd. G protein coupled receptor proteins, their production and use
US6268214B1 (en) 1996-04-04 2001-07-31 Roche Diagnostics Gmbh Vectors encoding a modified low affinity nerve growth factor receptor
US6004808A (en) * 1996-06-21 1999-12-21 Aurora Biosciences Corporation Promiscuous G-protein compositions and their use
FR2751535B1 (fr) * 1996-07-25 1998-11-27 Oreal Utilisation de derives de la melatonine pour la la depigmentation de la peau et compositions les comprenant
US6329197B2 (en) * 1996-10-09 2001-12-11 Synaptic Pharmaceutical Corporation DNA encoding galanin GALR3 receptors and uses thereof
US6087115A (en) * 1997-01-22 2000-07-11 Cornell Research Foundation, Inc. Methods of identifying negative antagonists for G protein coupled receptors
PT1012274E (pt) 1997-01-28 2007-08-14 Craig A Rosen Receptor 4 contendo um domínio de morte (dm4; receptor de morte 4), membro da super-família do ftn e ligação a liart (ap02)
US6403305B1 (en) 1997-02-06 2002-06-11 Cornell Research Foundation, Inc. Methods of identifying peptide agonists or negative antagonists of a G protein coupled receptor
US5891720A (en) * 1997-04-17 1999-04-06 Millennium Pharmaceuticals, Inc. Isolated DNA encoding a novel human G-protein coupled receptor
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US7541151B2 (en) 1997-06-05 2009-06-02 Duke University Single-cell biosensor for the measurement of GPCR ligands in a test sample
US5891646A (en) * 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
US6528271B1 (en) 1997-06-05 2003-03-04 Duke University Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
WO1998056892A1 (en) 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr9
US6183974B1 (en) 1997-07-31 2001-02-06 The General Hospital Corporation Screening assays for G protein coupled receptor agonists and antagonists
US5879665A (en) * 1997-09-25 1999-03-09 The Board Of Regents Of The University Of Oklahoma Composition for causing skin lightening
US5919436A (en) * 1997-09-25 1999-07-06 The Board Of Regents Of The University Of Oklahoma Method of lightening skin
US6110448A (en) * 1997-09-25 2000-08-29 The Board Of Regents Of The University Of Oklahoma Method for causing skin lightening
US20020146740A1 (en) * 1997-10-09 2002-10-10 William D. Huse Method for identifying optimal binding ligands to a receptor
WO1999051777A2 (en) * 1998-04-06 1999-10-14 Bunsen Rush Laboratories, Inc. Directed evolution biosensors
CA2334215A1 (en) * 1998-06-05 1999-12-16 Discovery Technologies Ltd. Transformed cell lines which express heterologous g-protein-coupled receptors
EP1123401A1 (en) * 1998-10-22 2001-08-16 The General Hospital Corporation BIOACTIVE PEPTIDES AND PEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHrP)
US20030017528A1 (en) * 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
US7816492B2 (en) * 1998-11-20 2010-10-19 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors
USRE42190E1 (en) 1998-11-20 2011-03-01 Arena Pharmaceuticals, Inc. Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors
WO2000032771A1 (en) 1998-11-30 2000-06-08 The General Hospital Corporation Pth1r and pth3r receptors, methods and uses thereof
DK1141237T3 (da) 1998-12-31 2006-02-13 Gen Hospital Corp PTH-receptor og screeningsassay der anvender denne
WO2000045179A2 (en) * 1999-01-27 2000-08-03 The Regents Of The University Of California Screening for modulators of g-protein subunit beta 3
US6929925B1 (en) 1999-01-27 2005-08-16 The Regents Of The University Of California Assays for sensory modulators using a sensory cell specific G-protein beta subunit
US6673554B1 (en) * 1999-06-14 2004-01-06 Trellie Bioinformatics, Inc. Protein localization assays for toxicity and antidotes thereto
AU7734800A (en) * 1999-09-29 2001-04-30 General Hospital Corporation, The Polypeptide derivatives of parathyroid hormone (pth)
US20050148018A1 (en) 1999-10-07 2005-07-07 David Weiner Methods of identifying inverse agonists of the serotonin 2A receptor
US7462457B2 (en) * 2000-08-30 2008-12-09 Johns Hopkins University School Of Medicine Identification of activated receptors and ion channels
US6913877B1 (en) 2000-09-11 2005-07-05 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Methods for detecting bioactive compounds
US20050059031A1 (en) * 2000-10-06 2005-03-17 Quantum Dot Corporation Method for enhancing transport of semiconductor nanocrystals across biological membranes
ATE536550T1 (de) * 2000-10-06 2011-12-15 Life Technologies Corp Halbleiter nanokristalle enthaltende transfektibare mizellen
US20020107193A1 (en) * 2000-11-09 2002-08-08 Glazner Gordon W. Therapeutic uses for IP3 receptor-mediated calcium channel modulators
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
AU2002250032B2 (en) 2001-02-09 2008-06-05 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
ES2299567T3 (es) 2001-05-05 2008-06-01 Smithkline Beecham Plc N-aroilaminas ciclicas.
CA2454275C (en) * 2001-07-23 2012-10-23 The General Hospital Corporation Conformationally constrained parathyroid hormone (pth) analogs
AU2002336504A1 (en) * 2001-09-12 2003-03-24 The State Of Oregon, Acting By And Through The State Board Of Higher Education On Behalf Of Oregon S Method and system for classifying a scenario
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
US20030166282A1 (en) 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
EP3415625A1 (en) * 2002-02-01 2018-12-19 Life Technologies Corporation Double-stranded oligonucleotides
US20050079526A1 (en) * 2002-02-20 2005-04-14 Affinium Pharmaceuticals, Inc. Methods and apparatuses for characterizing refolding and aggregation of biological molecules
US20030182669A1 (en) * 2002-03-19 2003-09-25 Rockman Howard A. Phosphoinositide 3-kinase mediated inhibition of GPCRs
US7290215B2 (en) * 2002-06-03 2007-10-30 Microsoft Corporation Dynamic wizard interface system and method
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
WO2004093902A1 (en) * 2003-03-19 2004-11-04 The General Hospital Corporation CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH α-HELIX STABILIZERS
ATE500270T1 (de) * 2003-05-20 2011-03-15 Univ Glasgow Materialien und methoden die sich auf g-protein gekoppelte rezeptor oligomere beziehen
EP1653985A4 (en) 2003-07-17 2009-08-05 Gen Hospital Corp CONSTRAINTS CONTAINING CONTAINING HORMONE PARATHYROID (PTH) ANALOGUES
WO2005105841A2 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
TW200539867A (en) * 2004-04-13 2005-12-16 Arena Pharm Inc Human g protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
CN101166527A (zh) 2005-04-27 2008-04-23 艾尼纳制药公司 用于治疗肥胖症和糖尿病以及其相关病况和用于治疗可通过增加血液glp-1含量改善的病况的组合疗法
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
DK1971862T3 (da) 2006-04-11 2011-02-14 Arena Pharm Inc Fremgangsmåder til anvendelse af GPR119-receptor til identificering af forbindelser anvendelige til øgning af knoglemasse hos en person
KR101356892B1 (ko) 2006-04-20 2014-01-28 지보당 에스아 미각자극물질을 동정하는 기능적인 방법
EP2047254B1 (en) 2006-04-20 2015-10-28 Givaudan SA Method relating to sweetness enhancement
WO2007142983A2 (en) * 2006-06-01 2007-12-13 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Microreactor process for making biodiesel
JP2009545320A (ja) * 2006-08-04 2009-12-24 ザ ジェネラル ホスピタル コーポレイション 副甲状腺ホルモン（ｐｔｈ）のポリペプチド誘導体
KR101511394B1 (ko) * 2007-01-18 2015-04-10 지보당 에스아 키메라 우마미 미각 수용체, 이를 코딩하는 핵산 및 이의 용도
JP5465656B2 (ja) 2007-03-30 2014-04-09 ジボダン エス エー 調節物質を同定するための方法
KR101661730B1 (ko) 2007-08-01 2016-10-04 더 제너럴 하스피탈 코포레이션 Ｇ―단백질 결합 수용체를 이용한 스크리닝 방법 및 관련 조성물
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
US8129384B2 (en) 2008-10-09 2012-03-06 Glaxo Group Limited Imidazo[1,2-a]pyrazines as orexin receptor antagonists
US8093255B2 (en) 2008-10-09 2012-01-10 Glaxo Group Limited Imidazo[1,2-A]pyrimidines as orexin receptor antagonists
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
AU2010240871A1 (en) 2009-04-24 2011-10-27 Glaxo Group Limited 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists
US20120149723A1 (en) 2009-08-24 2012-06-14 Romano Di Fabio 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder
JP2013502448A (ja) 2009-08-24 2013-01-24 グラクソ グループ リミテッド オレキシンアンタゴニストとして用いられるピペリジン誘導体
WO2011143406A2 (en) 2010-05-13 2011-11-17 The General Hospital Corporation Parathyroid hormone analogs and uses thereof
US10267796B2 (en) 2010-10-25 2019-04-23 The Procter & Gamble Company Screening methods of modulating adrenergic receptor gene expressions implicated in melanogenesis
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
WO2012089607A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
US9671410B2 (en) 2011-01-16 2017-06-06 The Procter & Gamble Company Biomarker-based methods for identifying and formulating compositions that improve skin quality and reduce the visible signs of aging in skin
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
CN107106429B (zh) 2014-11-10 2021-06-29 宝洁公司 具有两种有益相的个人护理组合物
US10966916B2 (en) 2014-11-10 2021-04-06 The Procter And Gamble Company Personal care compositions
US20160128927A1 (en) 2014-11-10 2016-05-12 The Procter & Gamble Company Personal Care Compositions With Two Benefit Phases
EP3697375B1 (en) 2017-10-20 2021-12-01 The Procter & Gamble Company Aerosol foam skin cleanser
EP3697374B1 (en) 2017-10-20 2022-02-16 The Procter & Gamble Company Aerosol foam skin cleanser
WO2020112486A1 (en) 2018-11-29 2020-06-04 The Procter & Gamble Company Methods for screening personal care products

Also Published As

Publication number Publication date
CA2087614A1 (en) 1992-01-20
US6051386A (en) 2000-04-18
DE69132564T2 (de) 2001-10-31
JP3270041B2 (ja) 2002-04-02
JPH06502757A (ja) 1994-03-31
DE69132564D1 (de) 2001-04-26
ES2157890T3 (es) 2001-09-01
EP0539518B1 (en) 2001-03-21
EP0539518A4 (ja) 1994-02-02
ATE199980T1 (de) 2001-04-15
US5462856A (en) 1995-10-31
EP0539518A1 (en) 1993-05-05
CA2087614C (en) 2009-09-01
WO1992001810A1 (en) 1992-02-06

Similar Documents

Publication Publication Date Title
DK0539518T3 (da) Fremgangsmåde til identifikation af forbindelser, der fungerer som agonister eller antagonister for proteiner, der er involveret i signaltransduktion
Pittman et al. Interactions of agonists and antagonists with beta-adrenergic receptors on intact L6 muscle cells.
Vaux et al. Social Support Resources, Behavior, and Appraisals: A Path Analysis.
Stewart et al. Na+, K+ and Ca2+ currents in identified leech neurones in culture
ATE13098T1 (de) Verwendung von in wasser dispergierbaren hydrophoben farbstoffen als markierungssubstanzen in immunologischen tests.
ATE100203T1 (de) Testverfahren.
WO1998010068A3 (en) Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
IL101233A (en) Receptor-based screening and identifying methods for amylin agonists and antagonists
Conti et al. The high variance of AMPA receptor-and NMDA receptor-mediated responses at single hippocampal synapses: evidence for multiquantal release
ES532280A0 (es) Un medio de ensayo para determinar la presencia de un ion en una muestra a ensayar
DE3588124D1 (de) Vorrichtung, mit Verwendung in chemischen Prüfverfahren
JPS55149049A (en) Testing method for corrosion evaluation of coated metal material and its apparatus
AU8749498A (en) Methods for identifying or screening agonists for and antagonists to ppar
AU645724B2 (en) Solid state ion sensor with silicone membrane
Giacobassi et al. An integrative approach to the facile functional classification of dorsal root ganglion neuronal subclasses
Bierkamp et al. Gastrin mediated cholecystokinin-2 receptor activation induces loss of cell adhesion and scattering in epithelial MDCK cells
NO960341L (no) Rekombinant C140-reseptor og dens agonister og antagonister
Perez-Polo et al. The preparation and properties of nerve growth factor protein at alkaline pH.
KR960702532A (ko) 인터루킨-5-수용체-의존성 세포 시그날 전달 경로에 대한 조절 효과를 갖는 물질을 스크리닝하는 방법(Process for screening substances having a modulating effect on an interleukine-5-receptor-dependent cellular signal transmission path)
CN113008965B (zh) 基于钴/吡咯/介孔碳的固体膜磷酸根离子选择性电极的制备方法与应用
Barovsky et al. Forskolin-stimulated cyclic AMP accumulation mediates protein synthesis-dependent refractoriness in C6-2B rat glioma cells.
Tkachuk Effect of pH on Ca-binding properties of calmodulin and on its interaction with Ca-dependent phosphodiesterase of cyclic nucleotides
Schild pA, a new scale for the measurement of drug antagonism. 1947.
Papke et al. Effects of pineal factors on the action potentials of sympathetic neurons.
KR970007350A (ko) 과량의 항원이 없는 단백질의 비탁 및 혼탁 측정법